Global Hyperphosphatemia Treatment Market is segmented By Product Type (Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Non-Phosphate Binders, Others) By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Hyperphosphatemia Treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2031 growing with a CAGR of XX% during the forecast period 2024-2031.
The global hyperphosphatemia treatment market is a growing due to increasing patient awareness of the phosphorus content of food, management of hyperphosphatemia on dialysis with ferric citrate etc.
The global hyperphosphatemia treatment market is driven by the factors such as rising incidence rates of hyperphosphatemia, rising demand for effective hyperphosphatemia treatment alternatives, growing number of patient on dialysis and increase number of products entering developing economies to increase the growth.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Product, Application, Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics
Rising Incidence Rates of Hyperphosphatemia also drives the Growth of the Hyperphosphatemia Treatment Market
Rising incidence rates of hyperphosphatemia are driving the hyperphosphatemia therapeutics market. For instance, on June 2022, As per the article published by the National Library of Medicine(NLM), Research revealed that the incidence of hyperphosphatasemia was 12% in all patients at admission to a tertiary care hospital, excluding patients with end-stage renal disease (ESRD), acute kidney injury (AKI), or phosphate levels that were not assessed at arrival.
Nephrologists frequently encounter hyperphosphatemia as a test abnormality. The frequency of hyperphosphatemia in ESRD patients ranges from 50 to 74%. According to one study, approximately 45% of children with oncologic illnesses who received liposomal amphotericin had hyperphosphatemia.
Poor Medication Adherance Among Patients due to High Pill Burdern Hamper the Market Growth
Poor medication adherance among patients due to a high pill burden hampers the growth of the hyperphosphatemia market in multiple ways. Primarily, because patients are not taking the medications as prescribed, there is less of an opportunity for the medications to be effective, and the market will not see the impact of the medications working.
Furthermore, because patients are not taking the prescribed medications correctly, the market will not see the expected sales growth. Finally, poor medication adherance can lead to drug resistance, which not only further harms patients but also limits options available to physicians in the hyperphosphatemia category Overall, poor medication adherance due to a high pill burden is a major factor that can negatively impact the market growth and slow down the market growth.
Segment Analysis
The global hyperphosphatemia treatment market is segmented based on product type, distributional channel and region.
The Sevelamer in Product Type Segment is dominating the Hyperphosphatemia market
Sevelamer has become a major player in the treatment of hyperphosphatemia, a condition found in patients with kidney failure. Its success in this market can be attributed to a number of factors.
First, Sevelamer is an effective treatment for hyperphosphatemia. It binds to phosphorus in the intestine and prevents its absorption into the bloodstream. This prevents the buildup of phosphorus in the body, which can lead to serious complications. Second, Sevelamer is well tolerated by patients. It has fewer side effects than many other drugs used to treat hyperphosphatemia. It's also easy to take, with only two tablets needed once a day. It will make it convenient for patients, improving adherence levels and treatment outcomes.
For instance, on march 2022, Lupin Limited (Lupin) announced the launch of Sevelamer Hydrochloride Tablets, 800 mg, after FDA approval.
Geographical Penetration
North America Accounted for Approximately 40.1% of the Market Share in 2022, Owing to region of some of the prominent market players
North America accounted for approximately 40.1% and expected to dominate the market in the forcast period. North America is dominating the hyperphosphatemia market due to several factors. Firstly, the region is home to some of the most prominent market players such as Ardelyx’s, Akebia Therapeutics and Pfizer. Companies have invested heavily in the research and development of new hyperphosphatemia drugs, enabling them to stay at the forefront of the market.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology firm developing therapeutics for kidney disease filed New Drug Application (NDA) for lanthanum dioxycarbonate (LDC), formerly known as Renazorb, with the Food and Drug Administration (FDA or Agency). LDC is a novel investigational drug being developed for the treatment of hyperphosphatemia in chronic renal disease dialysis patients.
Competitive Landscape
The major global players in the hyperphosphatemia treatment market include Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Lupin, Ardelyx, Akebia Therapeutics, Inc. Unicycive Therapeutics, Inc, CSL Vifor, Zeria Pharmaceutical.
Covid-19 Impact Analysis
The global pandemic caused by the novel coronavirus has significantly affected the hyperphosphatemia therapeutics market. The closure of medical facilities and pharmaceutical companies has disrupted the supply of drugs, leading to shortages in certain regions and delays in treatment delivery. With medical personnel being redeployed to care for COVID-19 patients, there is a shortage of healthcare professionals available to treat hyperphosphatemia.
This has resulted in reduced laboratory tests, medication delays, and rescheduled clinical appointments. Import restrictions on Active Pharmaceutical Ingredients (APIs) further strain the market, as manufacturers struggle to acquire sufficient quantities. Clinical trials for new treatments have also been delayed, impacting the development of innovative therapies. Overall, COVID-19 has significantly hindered the effectiveness of hyperphosphatemia therapeutics.
Russia Ukraine Conflict Analysis
The Russia-Ukraine War has had a limited but potentially significant impact on hyperphosphatemia therapeutics. The conflict has hindered medical aid to Ukraine, resulting in fewer resources available for treating hyperphosphatemia. Moreover, the unstable political situation has deterred potential investors from supporting medical research in the region, impeding progress.
However, there are potential positive outcomes. The war has led to a decrease in prices of raw materials used in hyperphosphatemia drug production, increasing affordability. This could enhance access to the drugs in the region. The long-term impact will depend on the evolving political climate and the ability to leverage cost reductions for wider benefit.
Segmentation Analysis
- By Product Type
- Sevelamer *
- Calcium-Based Phosphate Binders
- Iron-Based Phosphate Binders
- Lanthanum Carbonate
- Non-Phosphate Binders
- Others
- By Distributional Channel
- Hospital Pharmacy *
- Retail Pharmacy
- Online Stores
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- For instance, on July 2023, FDA panel backs Ardelyx CKD drug, despite agency concerns. The Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted yesterday by nine to four that the benefits of Xphozah (tenapanor) outweigh its risks when given as a monotherapy to treat high phosphate levels in the blood in adults with CDK who are on dialysis. The advisory committee was convened because Ardelyx launched an appeal against the FDA's issuance of a complete response letter (CRL) for Xphozah last year, which asked the company to carry out another clinical trial to show a greater effect on hyperphosphataemia, or a clinical endpoint associated with excess phosphate in dialysis patients.
- For instance, Nov, 2022, Unicycive completes enrollment of pivotal bioequivalence study for renazorb (lanthanum dioxycarbonate), an investigational treatment for hyperphosphatemia in chronic kidney disease (ckd) patients on dialysis. Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, stated that it has completed the enrollment of subjects in the RENAZORB bioequivalence (BE) study. RENAZORB (lanthanum dioxycarbonate) is an investigational phosphate binding agent utilizing proprietary nanoparticle technology that is being developed to treat hyperphosphatemia in CKD patients on dialysis.
- For instance, April, 2021 Ardelyx, Inc. has announced that its collaboration partner in japan, Kyowa Kirin Co., Ltd., has initiated four phase 3 clinical trials studies in japan evaluating tenapanor for hyperphosphatemia.
Why Purchase the Report?
- To visualize the global hyperphosphatemia treatment market segmentation based on product type, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of hyperphosphatemia treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global hyperphosphatemia treatment market report would provide approximately 53 tables, 51 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
